Oppenheimer raised the firm’s price target on Kymera Therapeutics (KYMR) to $120 from $67 and keeps an Outperform rating on the shares. The firm notes the company announced compelling early results in atopic dermatitis for lead asset, the oral STAT6-degrader, KT-621. Oppenheimer believes the results, while in a relatively small number of patients, support an efficacy and safety profile highly comparable to Regeneron’s (REGN) multi-blockbuster dupilumab. Further, it sees Monday’s results as supportive of a compelling product profile in both indications.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics price target raised to $127 from $73 at Morgan Stanley
- Kymera Therapeutics: Promising Phase 1b Trial Results and Competitive Edge Drive Buy Rating
- Promising Potential of Kymera Therapeutics’ KT-621: A Buy Rating Justified by Strong Clinical Trial Results
- Kymera Therapeutics price target raised to $125 from $98 at Piper Sandler
- Kymera Therapeutics price target raised to $110 from $80 at Citi